In simple terms, Nevro Corp. focuses on developing and providing medical devices that help manage chronic pain. They are known for their HFX spinal cord stimulation (SCS) system, which involves implanting a device that sends electrical signals to the spinal cord to reduce pain. This technology is particularly used for conditions like chronic back pain and painful diabetic neuropathy, aiming to offer significant relief without the need for medication or surgery.
Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.
“This transaction furthers our mission to become the preeminent musculoskeletal technology company in th...
